Waldenstrom’s macroglobulinemia (WM) is an indolent B-cell lymphoproliferative disorder which despite achieved successes in therapy is characterized by recurrences and refractoriness. Study of molecular biology allowed to use targeted drugs, in particular ibrutinib which acts through suppression of B cell receptor signaling pathway by inhibiting Bruton’s tyrosine kinase. In several large trials, ibrutinib demonstrated its effectiveness and manageable toxicity profile both in patients with newly diagnosed and recurrent/refractory WM. A clinical observation of a patient with WM is presented. Due to minimal response during previous treatment, the patient currently is undergoing monotherapy with ibrutinib with positive antitumor effect, satisfactory tolerability, and absence of significant adverse events. The effect of ibrutinib on humoral immunity during the follow up period was evaluated.

   For now days we don’t have any guidelines for the treatment of synchronous and metachronous tumors of the upper and lower gastrointestinal tract. In this case report, we are talking about optimal treatment strategy in a patient with early gastric cancer, a neuroendocrine tumor of the sigmoid colon, and a locally advanced rectal cancer. The patient underwent laparoscopic gastrectomy and endoscopic excision of the early neuroendocrine tumor of the sigmoid colon. View of the local advanced rectal cancer patient underwent combined preoperative “sandwich” treatment with 2 courses of chemotherapy before a long course of chemoradiotherapy and 2 courses of chemotherapy after. The treatment was well tolerated. Ten weeks later, the patient gets surgical procedure: laparoscopic low anterior resection with loop colostomy followed by adjuvant chemotherapy. At the end of chemotherapy colostomy closure was done. The minimally invasive surgical treatment is safe and feasible in patients with synchronous malignancies of upper and lower gastrointestinal tract. Fast track rehabilitation and minimal surgical trauma ensure timely delivery of chemotherapy.

   This paper describes the first experience of the department in using an electronic infusion pump in order to optimize and select an adequate and safe method of permanent analgesia in cardiac surgery patients in the perioperative period. Two clinical cases of using an infusion pump for continuous anesthesia are also presented. 

   The article presents a clinical case of a patient with locally advanced anaplastic thyroid cancer and concomitant cardiovascular pathology. Anaplastic thyroid cancer is a very rare and highly aggressive disease requiring long-term multistage treatment, often using cardiotoxic drugs. Combination of this pathology with ischemic heart disease affecting coronary arteries is a complex clinical problem requiring timely evaluation of cardiac risk at every stage. Treatment of this patient cohort is possible only by a multidisciplinary team of specialists.

   Multiple myeloma (MM) is a B-cell lymphoproliferative disorder. Its morphological substrate is plasma cells producing monoclonal immunoglobulin. Monoclonal light chains damage nephrons leading to development of acute kidney failure (AKF) which can be diagnosed at MM onset, recurrence, or progression. Dialysis-dependent kidney failure (DDKF) is associated with worse prognosis and decreased overall survival. Currently, the standard of MM therapy complicated by moderate and severe AKF is programs including bortezomib. According to the results of completed trials, achievement of hematological response plays the main role in AKF resolution, therefore, the use of new highly effective regimens of antitumor drug therapy is recommended. Despite the results of large clinical trials showing the effectiveness of daratumumab in therapy of patients with MM, data on its use in patients with newly diagnosed MM complicated by DDKF who are candidates for autologous hematopoietic stem cell transplant are limited. A case of daratumumab therapy (as monotherapy and in combination with lenalidomide, dexamethasone) of a 38-year-old female patient with MM complicated by DDKF and significant adverse events developed during previous short-term treatment with bortezomib is presented. The achieved hematological response (partial remission, absence of minimal residual disease), satisfactory somatic condition, as well as favorable daratumumab safety profile allowed to consider the patient for autologous hematopoietic stem cell transplant and increased the probability of improved renal response with subsequent cancellation of hemodialysis.

   Fecal DNA testing is a noninvasive method recommended by professional medical societies for colorectal cancer screening in individuals with intermediate risk of the disease. Adenamatous and serrated lesions, as well as cancer, lead to exfoliation of cells containing neoplastic altered DNA which, in turn, can be detected with sensitive testing methods aimed at specific genetic and epigenetic biomarkers. Mt-sDNA test approved by the United States Food and Drug Administration in 2014 showed sensitivity of 92 % for detection of colorectal cancer which is much higher than sensitivity of fecal immunochemical test (74 %).

   Currently, nausea and vomiting during chemotherapy are a common adverse event affecting quality and duration of life of patients. Introduction of several classes of antiemetics and correct use of various medications in the form of combination scheme of nausea and vomiting prophylaxis allow to effectively control these adverse events. However, the incidence of nausea and vomiting remains high in clinical practice, and according to surveys doctors underestimate the frequency of these complications in patients. This is primarily caused by patient noncompliance in using antiemetics for delayed nausea and vomiting prevention due to complicated schemes of dosing and frequency of antiemetic administration. Combination peroral drug netupitant + palonosetron (Akynzeo®) seems the optimal solution for this adverse event. One-time administration of Akynzeo® prior to chemotherapy course allows to omit 5-HT3 receptor agonists and NK1 receptor agonist for prevention of delayed nausea and vomiting which increases patient compliance in taking antiemetics due to simplified therapy regimen, decreases incidence of nausea and vomiting, and increases patients’ quality of life.